Breaking News

Pfizer Licenses OmniRat Antibody

Will use OMT’s platform for antibody R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Open Monoclonal Technology (OMT) and Pfizer have entered an agreement under which Pfizer will use OMT’s OmniRat for antibody R&D. OmniRat is a platform technology that generates fully human antibodies and enables developers to skip humanization of animal-derived antibodies or lead optimization of display candidates.   Dr. Roland Buelow, founder and chief executive officer of OMT, said, “OMT is pleased that Pfizer’s testing of our antibody platform showed that OmniRat makes antibodies j...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters